Iomeprol
(Synonyms: 碘美普尔) 目录号 : GC49729
A contrast reagent
Cas No.:78649-41-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Iomeprol is a nonionic and water-soluble contrast reagent.1,2 Formulations containing iomeprol have been used as radiocontrast agents in X-ray imaging.
1.AlmÉn, T.Visipaque - a step forward: A historical reviewActa Radiol.57(5)e47-e63(1995) 2.Ahn, Y.H., Koh, Y.I., Kim, J.H., et al.The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivityJ. Korean Med. Sci.30(3)245-251(2015)
| Cas No. | 78649-41-9 | SDF | Download SDF |
| 别名 | 碘美普尔 | ||
| Canonical SMILES | O=C(C1=C(I)C(N(C)C(CO)=O)=C(I)C(C(NCC(CO)O)=O)=C1I)NCC(CO)O | ||
| 分子式 | C17H22I3N3O8 | 分子量 | 777.1 |
| 溶解度 | DMSO: slightly soluble,Methanol: slightly soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2868 mL | 6.4342 mL | 12.8684 mL |
| 5 mM | 0.2574 mL | 1.2868 mL | 2.5737 mL |
| 10 mM | 0.1287 mL | 0.6434 mL | 1.2868 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Iomeprol: a review of its use as a contrast medium
Drugs 2000 May;59(5):1169-86.PMID:10852647DOI:10.2165/00003495-200059050-00013.
Iomeprol is a nonionic, monomeric iodinated contrast medium. Unlike the older ionic agents, Iomeprol has low chemotoxicity, osmolality and viscosity and high water solubility. Compared with other nonionic contrast media, the osmolality and viscosity are lower and the water solubility is reported to be higher with Iomeprol. Most radiographs (about 67 to 100%) obtained with Iomeprol (containing 150 to 400 mg/ml of iodine) were of good or excellent quality in noncomparative and comparative trials recruiting 40 to 6127 patients undergoing various radiographic procedures. As expected, the diagnostic efficacy of Iomeprol did not differ significantly from that of other nonionic agents (iopamidol, iopromide, iohexol and iotrolan). Iomeprol (containing 150 to 400 mg/ml of iodine) was well tolerated in clinical trials. Most adverse events were transient and of mild to moderate intensity and were similar to those observed with other contrast media. The overall incidence of adverse events ranged from 3 to 49.7% and mainly included localised pain (< or =6%) and heat sensations (8 to 45%), taste disturbances (3 to 27%) and various pseudoallergic reactions (< or =20% for each type of event). The incidence of heat or pain and taste disturbances with Iomeprol was similar to that observed with iopromide and iopamidol. Pain (but not heat sensations) was reported significantly less frequently and taste disturbances reported significantly more frequently with Iomeprol than with iohexol in a comparative trial. Pseudoallergic reactions (such as nausea, vomiting, skin reactions, dizziness, headache) were significantly less common with Iomeprol than with ioxaglate and occurred at a similar frequency to that with iopromide and iopamidol. Cardiovascular events were rarely observed with Iomeprol. Currently available Iomeprol solutions contain a range of iodine concentrations (150 to 400 mg/ml) and are approved for a wide variety of diagnostic procedures. Iomeprol solutions are chemically stable which negates the need for chelating agents. Formulations of this agent are therefore the first not to contain edetic acid (EDTA). Conclusions: Iomeprol shows equivalent diagnostic efficacy, and a similar adverse event profile, to that of other nonionic contrast media. The availability of a range of iodine concentrations enables Iomeprol to be used in a variety of diagnostic procedures. Iomeprol, like others in its class, is suitable for use in diagnostic imaging.
Clinical pharmacology of Iomeprol
Eur J Radiol 1994 May;18 Suppl 1:S51-60.PMID:8020519DOI:10.1016/0720-048x(94)90094-9.
The pharmacodynamic effects of Iomeprol on the cardiovascular, central nervous, coagulation, and complement systems and on renal and thyroid functions using a wide range of intravenous and intraarterial radiological procedures were evaluated in Phase I, Phase II and Phase III clinical studies. The pharmacokinetics and metabolism of Iomeprol were studied in healthy volunteers. Iomeprol 350 and 400 mgI/ml at doses ranging from 100 to 300 ml did not cause any significant changes of the basal haemodynamic parameters when used in CT of the chest and upper abdomen. No significant alterations of haemodynamic and ECG parameters were seen in patients who underwent cardiac-angiography or coronary angiography with Iomeprol 400 mgI/ml. Intensive monitoring of haemodynamic and EEG parameters in patients undergoing conventional cerebral angiography with Iomeprol 300 mgI/ml confirmed good toleration by the CNS. Neither renal and thyroid functions nor the coagulation and complement systems were significantly affected by Iomeprol. Iomeprol was not metabolised and did not bind to plasma proteins. In healthy volunteers it was excreted almost exclusively by renal glomerular filtration (about 90% of the injected dose after 24 h). The pharmacokinetic behaviour of Iomeprol was very similar to the behaviour of other nonionic, monomeric agents.
Clinical utility and safety profile of Iomeprol
Eur J Radiol 1994 May;18 Suppl 1:S120-4.PMID:8020514DOI:10.1016/0720-048x(94)90106-6.
Iomeprol is a new triiodinated, nonionic radiographic contrast agent prepared for injection at a number of concentrations (150, 200, 250, 300, 350 and 400 mgI/ml), each of which has osmolality and viscosity properties that are more favourable than other current nonionic monomers at the same iodine concentrations. Pharmaco-toxicological studies in animals have demonstrated that the molecular toxicity of Iomeprol is very low. Intensive monitoring of vital, electro-physiological, and biochemical parameters in clinical studies have shown that Iomeprol does not have clinically significant effects on the more important body systems and functions. Out of 7799 patients to whom Iomeprol was administered, adverse events were observed in only 437 (5.6%). Of these events, the majority were rated as mild. In double-blind controlled clinical studies the contrast efficacy of Iomeprol was shown to be as good as that of reference contrast media. The good efficacy was confirmed in a very large number of uncontrolled studies.
Iomeprol: current and future profile of a radiocontrast agent
Invest Radiol 2001 Feb;36(2):87-96.PMID:11224756DOI:10.1097/00004424-200102000-00004.
Rationale and objectives: To review the safety and efficacy profiles of Iomeprol by examining the most indicative comparative clinical studies of Iomeprol with widely used low-osmolar ionic or nonionic contrast agents, and to illustrate the recent development in Iomeprol liposomal formulations for liver imaging and intravascular enhancement. Methods: Randomized, double-blind, comparative studies were performed of Iomeprol versus iopamidol, iopromide, ioxaglate, iopentol, iodixanol, ioversol, and iohexol. In all studies, safety controls included pre- and postadministration physical examinations, monitoring of vital signs, electrocardiography, clinical laboratory investigations, and 24- or 72-hour postadministration monitoring of patients for adverse events. Technically adequate images were rated for diagnostic efficacy by masked assessors. Results: Iomeprol showed similar safety and diagnostic efficacy compared with the nonionic monomers iopamidol, iohexol, and ioversol, and no statistically significant differences were observed. No differences in diagnostic efficacy between Iomeprol and iopromide were observed, but in one study on 1,200 patients, the incidence of adverse events and adverse reactions was significantly higher with iopromide than with Iomeprol. Iomeprol caused significantly less heat/pain than iopentol in one study; it showed similar safety and tolerability to the nonionic dimer iodixanol, the two agents causing no or modest, superimposable pain and heat sensation at injection and showing similar renal tolerability after intra-arterial injection. A comparison of Iomeprol versus ionic dimer ioxaglate in 2,000 patients undergoing percutaneous coronary interventions showed that the incidence of thrombus-related events was similar with the two agents, but ioxaglate caused a significantly higher incidence of allergy-like reactions. First results with iomeprol-containing liposomal formulations show that these agents may facilitate the CT assessment of intrahepatic malignancies and CT angiography procedures. Conclusions: The overall results of numerous randomized, double-blind, comparative clinical studies in a variety of indications show that the diagnostic efficacy of Iomeprol solutions does not differ significantly from that of the low-osmolar contrast media available on the marketplace when similar iodine strengths are used, although Iomeprol may have better tolerability and safety than the ionic dimer and some of the nonionic monomers in selective applications. First results obtained with iomeprol-containing liposomal formulations are promising and may foster additional clinical testing.
Non-immediate hypersensitivity reactions to Iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media
Allergy 2022 Dec;77(12):3641-3647.PMID:35815908DOI:10.1111/all.15433.
Background: Iodinated contrast media produce non-immediate hypersensitivity reactions (NIHR). The goal of this prospective study was to determine the utility of skin tests and the subsequent tolerance to negative skin-tested iodinated contrasts in patients with NIHR caused by Iomeprol. Methods: Prick and intradermal tests with Iomeprol, iopamidol, iopromide, and iobitridol were performed in all patients. IV challenge with the causative contrast (Iomeprol in 90%) was made if skin tests were negative. In case of a positive skin test with the causal contrast, or a positive challenge test with it, IV challenge test with an alternative, negative skin-tested contrast was performed in all patients. Results: Skin tests were positive in 47.6% (20/42) of patients with NIHR induced by Iomeprol. Of the 66 challenge tests performed with negative skin-tested iodinated contrasts, tolerance was confirmed in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol. Cross-reactivity between Iomeprol and iopamidol was 22% (4/20 in patients with positive skin tests and 5/21 in patients with negative skin tests). Conclusions: Sensitivity of the skin tests was less than 50% NIHRs due to Iomeprol, while the negative predictive value of skin tests in patients who tolerated challenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed). The cross-reactivity between Iomeprol and iopamidol is high.